Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | US

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
IRLAB Therapeutics Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.	Sweden	IRLAB
IRONWOOD PHARMACEUTICALS INC Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.	United States of America	IRWD
ISU Abxis Co., Ltd. Developing antibody-based immunotherapies for oncology and rare diseases.	South Korea	086890
Iterum Therapeutics plc Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.	United States of America	ITRM
IVF HARTMANN Holding AG Produces and distributes medical supplies, wound care, and hygiene items for global healthcare.	Switzerland	VBSN
Jade Biosciences, Inc. Clinical-stage biotech developing therapies for autoimmune and inflammatory diseases.	United States of America	JBIO
Jaguar Health, Inc. Develops plant-based, non-opioid GI therapies for humans and animals.	United States of America	JAGX
Janux Therapeutics, Inc. Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.	United States of America	JANX
Japan Tissue Engineering Co., Ltd. Pioneers regenerative medicine with tissue products, CDMO services, and research models.	Japan	7774
Jasper Therapeutics, Inc. Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.	United States of America	JSPR